Evaluation of c-erbb-2 overexpression and Her-2/neu gene copy number heterogeneity in Barrett s adenocarcinoma

Similar documents
792 Laboratory Investigation June 2001 Volume 81 Number 6. Results

HER2 CISH pharmdx TM Kit Interpretation Guide Breast Cancer

Priti Lal, MD, 1 Paulo A. Salazar, 1 Clifford A. Hudis, MD, 2 Marc Ladanyi, MD, 1 and Beiyun Chen, MD, PhD 1. Abstract

HER2 FISH pharmdx TM Interpretation Guide - Breast Cancer

Considerable advances in the therapy of breast cancer

HER-2/neu amplification detected by fluorescence in situ hybridization in fine needle aspirates from primary breast cancer

T he HER2/neu type 1 tyrosine kinase growth factor

Dr. dr. Primariadewi R, SpPA(K)

Product Introduction

Three Hours Thirty Minutes

IT S ABOUT TIME. IQFISH pharmdx Interpretation Guide THREEHOURSTHIRTYMINUTES. HER2 IQFISH pharmdxtm. TOP2A IQFISH pharmdxtm

Determination of HER2 Amplification by In Situ Hybridization. When Should Chromosome 17 Also Be Determined?

Comparison of Fluorescence and Chromogenic In Situ Hybridization for Detection of HER-2/neu Oncogene in Breast Cancer

Journal of Breast Cancer

Comparison of Immunohistochemical and Fluorescence In Situ Hybridization Assessment of HER-2 Status in Routine Practice

HER2 ISH (BRISH or FISH)

HER2 status assessment in breast cancer. Marc van de Vijver Academic Medical Centre (AMC), Amsterdam

KEY WORDS: Breast carcinoma, c-erbb2, Fluorescent. Mod Pathol 2001;14(11):

MEDICAL POLICY. Proprietary Information of YourCare Health Plan

Dako IT S ABOUT TIME. Interpretation Guide. Agilent Pathology Solutions. ALK, ROS1 and RET IQFISH probes (Dako Omnis) MET IQFISH probe (Dako Omnis)

Assessment Run B HER2 IHC

Technique and feasibility of a dual staining method for estrogen receptors and AgNORs

Assessment Run B HER-2 IHC. HER-2/chr17 ratio**

HER2/neu Amplification in Breast Cancer Stratification by Tumor Type and Grade

Immunohistochemical (IHC) HER-2/neu and Fluorescent- In Situ Hybridization (FISH) Gene Amplification of Breast Cancer in Indian Women

MEDICAL POLICY. Proprietary Information of Excellus Health Plan, Inc. A nonprofit independent licensee of the BlueCross BlueShield Association

Applications of IHC. Determination of the primary site in metastatic tumors of unknown origin

Assessment Run B HER2 IHC

Instant Quality FISH. The name says it all.

PD-L1 Analyte Control DR

Gastric Carcinoma with Lymphoid Stroma: Association with Epstein Virus Genome demonstrated by PCR

Case Report Aggressive invasive micropapillary salivary duct carcinoma of the parotid gland

Comparative Analysis of Methods Used in Breast Cancer HER2 and Sentinel Lymph Node Diagnosis

Detection of Anaplastic Lymphoma Kinase (ALK) gene in Non-Small Cell lung Cancer (NSCLC) By CISH Technique

Kristen E. Muller, DO, Jonathan D. Marotti, MD, Vincent A. Memoli, MD, Wendy A. Wells, MD, and Laura J. Tafe, MD

Significance of HER2 Low-Level Copy Gain in Barrett s Cancer: Implications for Fluorescence In situ Hybridization Testing intissues

Instant Quality FISH. The name says it all.

Oncology Genetics: Cytogenetics and FISH 17/09/2014

HER2/neu Evaluation of Breast Cancer in 2019

# Best Practices for IHC Detection and Interpretation of ER, PR, and HER2 Protein Overexpression in Breast Cancer

Comparison of in situ hybridization methods for the assessment of HER-2/neu gene amplification status in breast cancer using a tissue microarray

Evolution of Pathology

Evaluation of HER2/neu oncoprotein in serum and tissue samples of women with breast cancer: Correlation with clinicopathological parameters

Next-Generation Immunohistochemistry: Multiplex tissue imaging with mass cytometry

Assessment Run GATA3

Breast Cancer Interpretation Guide

Single and Multiplex Immunohistochemistry

IMMUNOHISTOCHEMICAL EXPRESSION OF TISSUE INHIBITOR OF METALLOPROTEINASE-1 (TIMP-1) IN INVASIVE BREAST CARCINOMA

Image analysis in IHC overview, considerations and applications

Assessment of Breast Cancer with Borderline HER2 Status Using MIP Microarray

Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Molecular Probes Introducing 14 new probes

Estrogen receptor (ER)

HER-2/neu Marker Examination using Immunohistochemical Method in Patients Suffering from Gastric Adenocarcinoma

HER2 Status and Its Heterogeneity in Gastric Carcinoma of Vietnamese Patient

Layered-IHC (L-IHC): A novel and robust approach to multiplexed immunohistochemistry So many markers and so little tissue

FAQs for UK Pathology Departments

The estimation of tumor cell percentage for molecular testing by pathologists is not accurate

CANCER. Clinical Validation of Breast Cancer Predictive Markers

Characterization and significance of MUC1 and c-myc expression in elderly patients with papillary thyroid carcinoma

Journal of Breast Cancer

Interpretation Manual - Gastric or Gastroesophageal Junction Adenocarcinoma. PD-L1 IHC 22C3 pharmdx is FDA-approved for in vitro diagnostic use

Supplementary Figure 1

Immunohistochemical Determination of HER-2/neu Expression in Invasive Breast Carcinoma

The following slides were presented at the TIGA Workshop, and are enclosed in the PP show format (*.pps) in order to include all presented details.

Estrogen Receptor, Progesterone Receptor, and Her-2/neu Oncogene Expression in Breast Cancers Among Bangladeshi Women

High expression of fibroblast activation protein is an adverse prognosticator in gastric cancer.

Research Article Stromal Expression of CD10 in Invasive Breast Carcinoma and Its Correlation with ER, PR, HER2-neu, and Ki67

Editorial New guidelines for HER2 pathological diagnostics in gastric cancer

Version 2 of these Guidelines were drafted in response to published updated ASCO/CAP HER2 test Guideline Recommendations-

Clonal evolution of human cancers

Assessment Run B HER-2

Supplementary Information. Detection and delineation of oral cancer with a PARP1 targeted optical imaging agent

INTRODUCTION TO PATHOLOGICAL TECHNIQUES. 1. Types of routine biopsy procedures 2. Special exams (IHC, FISH)

Citation Acta Medica Nagasakiensia. 1992, 37

Significance of Chromosome Changes in Hematological Disorders and Solid Tumors

Significance of Chromosome Changes in Hematological Disorders and Solid Tumors

Patterns of E.cadherin and Estrogen receptor Expression in Histological Sections of Sudanese Patients with Breast Carcinoma

Expression and Significance of GRP78 and HER-2 in Colorectal Cancer

Supplementary Appendix

S Wang, M H Saboorian, E Frenkel, L Hynan, S T Gokaslan, R Ashfaq

SMH (Myosin, smooth muscle heavy chain)

(A) PCR primers (arrows) designed to distinguish wild type (P1+P2), targeted (P1+P2) and excised (P1+P3)14-

Guideline. Associated Documents ASCO CAP 2018 GUIDELINES and SUPPLEMENTS -

Sonic hedgehog expression in gastric cancer and gastric adenoma

Changes in Protein Expression in Breast Cancer after Anthracycline- Based Chemotherapy

Milestones in Her 2 Testing

Hypoxia inducible factor-1 alpha and carbonic anhydrase IX overexpression are associated with poor survival in breast cancer patients

Quality in Control. ROS1 Analyte Control. Product Codes: HCL022, HCL023 and HCL024

Technical Advance. Chromogenic in Situ Hybridization

P16 INK4A EXPRESSION AS A POTENTIAL PROGNOSTIC MARKER IN CERVICAL PRECANCEROUS AND CANCEROUS LESIONS IN MOROCCO

Cell Culture. The human thyroid follicular carcinoma cell lines FTC-238, FTC-236 and FTC-

Asian J Androl 2008; 10 (5): DOI: /j x

7/6/2015. Cancer Related Deaths: United States. Management of NSCLC TODAY. Emerging mutations as predictive biomarkers in lung cancer: Overview

Contributions to Anatomic Pathology, over the years

HPV/p16 Analyte Control

Her-2/neu expression and its correlation with ER status and various clinicopathological parameters

The diagnostic and prognostic value of genetic aberrations in resectable distal bile duct cancer Rijken, A.M.

Immune Cell Phenotyping in Solid Tumors using Quantitative Pathology

Transcription:

25 Evaluation of c-erbb-2 overexpression and Her-2/neu gene copy number heterogeneity in Barrett s adenocarcinoma Axel Walch a,, Karin Bink b, Peter Gais a, Stefan Stangl a, Peter Hutzler a, Michaela Aubele a, James Mueller c,heinzhöfler a,b and Martin Werner b a GSF-National Research Center for Environment and Health, Institute of Pathology, Neuherberg, Germany b Technical University Munich, Institute of Pathology, Munich, Germany c Technical University Munich, Department of Surgery, Munich, Germany Received 3 December 1999 Accepted 14 March 2000 Amplifiction of the Her-2/neu gene is accompanied by overexpression of its cell surface receptor product, c-erbb-2 protein. To investigate the degree of intratumoural heterogeneity we applied immunohistochemistry in primary Barrett s adenocarcinoma (BCA) (n = 6) and dysplasia adjacent to the carcinoma (n = 4). In addition, fluorescence in situ hybridisation (FISH) was performed in primary BCA (n = 5) and dysplastic areas (n = 4). For an objective evaluation digital image analysis and laser scanning microscopy were used. Five of six BCA showed a marked intratumoural heterogeneous staining pattern ranging from areas in which the tumour cells were negative or faintly positive to tumour areas with a strong staining of the entire membrane. Among the two dysplastic areas also a heterogenous staining pattern was observed. FISH analysis revealed marked heterogeneity of intratumoural gene copy number changes in all BCA showing populations with different fractions of cells with polysomy, low level amplification and high level amplification. One dysplasia showed a minor population with Her- 2/neu signal clusters. In conclusion, we observed marked intratumoural heterogeneity of c-erbb-2 protein overexpression and Her-2/neu gene copy number in the majority of * Corresponding author: Dr. med. Axel Walch, GSF-Forschungszentrum für Umwelt und Gesundheit, Institut für Pathologie, Ingolstädter Landstraße 1, D-85764 Oberschleißheim, Germany. Tel.: +49 89 31872739; Fax: +49 89 31873349; E-mail: Walch@gsf.de. the primary BCA analyzed. Digital image analysis and laser scanning microscopy were helpful in quantifying the variations in protein expression and DNA copy number in individual tumour cells. The observed heterogeneity could hamper the exact diagnostic determination of the c-erbb-2 status in small biopsies and possibly influence the effectiveness of a potential c-erbb-2 targeting therapy. Figures on http://www.esacp.org/acp/2000/20-1/walch.htm. Keywords: Intratumoural heterogeneity, Her-2/neu, c-erbb- 2, fluorescence in situ hybridization, immunohistochemistry, laser scanning microscopy, digital image analysis, Barrett s adenocarcinoma, dysplasia 1. Introduction One of the best characterized oncogenes is Her- 2/neu (erbb-2) which encodes a 185,000 molecular weight transmembrane tyrosine kinase (c-erbb-2). When the Her-2/neu oncogene is activated by gene amplification c-erbb-2 protein is overexpressed [3,4]. The most common methods for the demonstration of Her- 2/neu oncogene activation in tumour cells are immunohistochemistry (IHC) which shows protein expression at the cell membrane, and fluorescence in situ hybridization (FISH) for the detection of increased DNA copy numbers in tumour cell nuclei [3]. A variety of human tumours show c-erbb-2 overexpression or Her-2/neu gene amplification, among these are carcinomas of breast, lung, bladder and colon [4]. In some tumour types c-erbb-2 overexpression has been correlated with poor prognosis [3] or a lack of response to chemotherapy [3,4]. Barrett s adenocarcinoma (BCA) of the esophagus has been reported to display increased c-erbb-2 expression in up to 26% of cases by immunohistochemistry [1,7]. On the DNAlevel, we previously demonstrated amplification of the long arm of chromosome 17 including the Her-2/neu locus in 30% of BCA [5]. It is not known whether individual cases of BCA have homogeneous c-erbb-2 overexpression and Her- Analytical Cellular Pathology 20 (2000) 25 32 ISSN 0921-8912 / $8.00 2000, IOS Press. All rights reserved

26 A. Walch et al. / c-erbb-2 overexpression and Her-2/neu gene in BCA 2/neu gene amplification or if these findings show a more heterogeneous pattern with varying degrees of positivity throughout the tumour. Marked heterogeneity could have an impact on the diagnostic determination of c-erbb-2 status in small biopsies and could influence the effectiveness of potential c-erbb-2 targeting therapy. The aim of the present study was therefore to evaluate the pattern of c-erbb-2 expression in different areas of BCA by immunohistochemistry. The results were correlated with the results of FISH for the Her-2/neu oncogene in some of the cases. 2. Material and methods 2.1. Tissue samples All analyses were performed on archival material from formalin-fixed (4% buffered formalin) and paraffin-embedded tissue obtained from six patients with primary Barrett s adenocarcinoma (BCA) of the distal esophagus. All patients underwent an esophagectomy without preoperative radiotherapy or chemotherapy. Serial sections were cut for immunohistochemistry (5 µm) and fluorescence in situ hybridization (10 µm). The first and the last section of each series was stained with H&E. Corresponding areas on sequential sections were investigated by both methods. 2.2. Immunohistochemistry (IHC) The sections for immunohistochemistry were deparaffinized and rehydrated. Antigen retrieval was performed by heating the sections in a microwave oven for 30 min at 750 W. During heating the sections were immersed in a citric buffer (ph 6.0). After cooling the sections to room temperature, endogenous peroxidase activity was blocked by incubation with 3% hydrogen peroxidase in methanol for 15 min. The sections were then incubated for 15 min with phosphate buffered saline containing 10% serum at 37 C. Anti-c-erbB-2 antibody (DAKO, Glostrup, Denmark) was applied at a dilution of 1 : 400 and incubated for 1 h at 25 Cfollowed by detection with a DAKO ChemMate TM detection kit containing peroxidase and DAB, according to the manufacturer s recommendations. Finally, the slides were counterstained with hematoxylin, dehydrated and coverslipped. To ensure the sensitivity of the reaction, a case of invasive ductal breast carcinoma with known overexpression of c-erbb-2 was used as positive control. 2.3. Fluorescence in situ hybridization (FISH) For FISH analysis a PathVysion Her-2/neu DNA probe kit (Vysis, Inc.; Downers Grove, United Kingdom) was used according to the manufacturer s recommendations. The kit consists of directly labelled fluorescent DNA probes specific for the HER-2/neu gene locus (17q11.2 q12) and a DNA probe specific for the alpha satellite DNA sequence at the centromeric region of chromosome 17 (17p11.1 q11.1). Tissue pretreatment was performed as previously decribed [6]. Counterstaining of nuclei was performed using TO-PRO TM -3 iodide (Molecular Probes, Eugene, USA). Nuclei from normal squamous epithelium or lymphocytes deposited separately on the same slide were used as controls of hybridisation efficiency and specificity. 2.4. Evaluation of immunohistochemical staining 2.4.1. Visual evaluation c-erbb-2 protein overexpression was evaluated by two experienced pathologists (M.W., A.W.) according to a score system recommended by the DAKO HercepTest TM. Briefly, complete lack of staining, or membranous staining in less than 10% of the tumour cells was scored as 0. If faint or barely perceptible membranous staining was detected in more than 10% of the tumour cells, or cells showed only partial membranous staining they were scored as 1+. A score of 2+ was defined as weak to moderate staining of the entire membrane in more than 10% of the tumour cells. Finally, strong staining of the entire membrane in more than 10% of the tumour cells was score as 3+. 2.4.2. Evaluation by digital image analysis Using an Orthoplan microscope (Leica, Bensheim, Germany, objective 25, numerical aperture 0.55) equipped with a color TV camera (JVC KY-F30, 3- CCD, 640 480 pixels, Tokyo, Japan) and a SAMBA 2005 image analysis system (Systeme d Analyses Microscopique a Balayage Automatique, UNILOG, Meylan, France) images were taken with a grid measuring 500 µm 2 over the entire tumour areas by the investigator (P.G.). The features of the neoplastic cells were calculated with software developed in our own laboratory. The integrated optical density (IOD), mean optical density (MOD), standard deviation (STDV) and range of the marked tumour areas were calculated after performing a shading correction. The measurements were made in the blue channel of the RGB TV-signal which was adjusted to correspond to the staining of the slides.

A. Walch et al. / c-erbb-2 overexpression and Her-2/neu gene in BCA 27 2.5. Evaluation of FISH signals 2.5.1. Visual evaluation Each of the cases was visually evaluated by two experienced investigators (A.W., K.B.) using a fluorescence microscope. The criteria established by Hopman et al. were followed for signal enumeration [2]. The Her-2/neu gene locus was classified as amplified if there were more than twice as much red Her-2/neu signals than green centromere 17 signals (ratio > 2, low level amplification). More than two red signals accompanied by the same number of green signals was considered to be indicative of polysomy of chromosome 17. Her-2/neu clusters were defined as an accumulation of usually more than 10 signals, reflecting a high level gene amplification. In those cells the precise number of signals could not be counted due to coalescent signal clusters. The tumours were classified as no amplification, low-level amplification or high-level amplification of Her-2/neu gene copy number depending on the most prevalent cell population. The results were compared with those obtained by laser scanning microscopy. 2.5.2. Evaluation by laser scanning microscopy Using a confocal laser scanning microsope (Zeiss LSM 510) 15 20 randomly selected fields (objective 63 ) within carcinomatous and dysplastic areas were scanned in steps of 0.5 µm. Cells were selected for scoring according to morphological criteria using TO-PRO TM -3 iodide staining. To avoid misinterpretation due to insufficient hybridization, cells were counted only if at least one bright centromere signal and one Her-2/neu signal were present. Signals from all neoplastic cell nuclei within the 15 20 randomly selected high-power fields were counted, and the abovementioned criteria were followed for classification. 3. Results Figures on http://www.esacp.org/acp/2000/20-1/ walch.htm. 3.1. C-erbB-2 protein overexpression Figure 1 shows the corresponding frequency distribution of staining intensity for e-erbb-2 oncoprotein of Fig. 1. The frequency distribution of staining intensity of c-erbb-2 protein of the six cases of BCA. The mean values of these distributions are summarized in Table 1. Note that the level of heterogeneity (width of the intensity profiles on this intensity scale) is different in the six cases and the absolute c-erbb-2 overexpression varies from case to case.

28 A. Walch et al. / c-erbb-2 overexpression and Her-2/neu gene in BCA Fig. 2. Heterogeneous pattern of c-erbb-2 immunostaining in six BCA. #1, #3, #4, #5, #6 note the marked intratumoural heterogeneity of c-erbb-2 overexpression; #2, virtually every cell is strongly immunopositive. the whole tumour areas of the six cases of BCA. Figure 2 illustrates the level of intratumoural heterogeneity of c-erbb-2 overexpression in the six cases of BCA. The mean values of the distribution curves and the results of visual evaluation are summarized in Table 1. 3.1.1. Visual evaluation According to the used scoring system four of six BCA were scored as 3+, one as 2+ and one as 1+. However, five of six BCA showed a marked intratumoural heterogeneous staining pattern ranging from areas in which the tumour cells were negative (score 0 ) or faintly positive (score 1+ or 2+ ) to tumour areas with a strong staining of the entire membrane (score 3+ ). Only one BCA demonstrated a homogenous staining pattern in which virtually every tumour cell was strongly immunopositive (score 3+). Among the two dysplatic areas also a heterogenous staining pattern was observed. Both dysplastic areas were scored as 1+. 3.1.2. Evaluation by digital image analysis Six BCA ranged from 49.2 to 116.0 MOD. All cases except one displayed striking differences in the staining intensities due to different tumour areas analyzed (Fig. 2). The two dysplastic areas showed a MOD of 43.8 and 45.0 (Table 1).

A. Walch et al. / c-erbb-2 overexpression and Her-2/neu gene in BCA 29 Table 1 Results of IHC and FISH. C-erbB-2 overexpression of six Barrett s adenocarinomas (CA) and two adjacent dysplasias (DYS). Corresponding FISH analysis of Her-2/neu gene and centromere 17 in two cases of Barrett s adenocarcinoma and two adjacent dysplasia IHC Evaluation by digital image analysis Visual evaluation Case MOD STDV Range CV Score 1 #1 CA 85.3 22.9 108 34 3+ #2 CA 90.8 9.7 51.5 10.6 3+ #3 CA 116 18.8 124 16.6 3+ #3 Dys 43.8 9.9 26.1 24.1 1+ #4 CA 49.2 8.4 60.3 23.7 1+ #5 CA 80.9 8.4 41.2 11.2 2+ #6 CA 76 24.9 89 41.5 3+ #6 Dys 45 8.9 61.0 21.7 1+ FISH Evaluation by laser scanning microscopy Visual evaluation Case n 2 Her-2/neu Her-2/neu Chr. 17 Her-2/neu Classification -cluster (%) 3 signals 4 signals 5 /chr. 17 #2 CA 144 29 2.1 2.1 0.9 Low level amplification #3 CA 280 75 0.5 2.7 0.2 High level amplification #3 Dys 233 12 1.1 2.7 0.4 No amplification #4 CA 283 7.4 2.5 1.7 1.5 No amplification #6 CA 264 87 1.1 2.8 0.4 High level amplification #6 Dys 229 0 0.5 1.8 0.3 No amplification MOD, mean optical density; STDV, standard deviation; CV, coefficient of variation; 1 Score system for the determination of c-erbb-2 protein overexpression, as provided for DAKO Hercept Test TM ; 2 total number of evaluated neoplastic cells per 15 20 randomly selected high power fields within a histopathologically defined area; 3 number of cells with Her-2/neu signal clusters, precise number of signals in these cells could not be counted due to coalescent signals cluster. The clusters were usually composed of more than 10 signals; 4 mean number of Her-2/neu signals in remaining neoplastic cells; 5 mean number of chromosome 17 signals per neoplastic cell. 3.1.3. Her-2/neu gene copy number Table 1 provides a comparison between visual evaluation and evaluation by laser scanning microscopy. 3.1.4. Visual evaluation Two from four BCA were diagnosed as high level amplified, one as low level amplified and one as not amplified. Striking heterogenetiy of intratumoural gene copy number changes was observed in all BCA showing populations with different fractions of cells with polysomy, low level amplification and high level amplifiaction. Figure 3 illustrates intratumoural heterogeneityof Her-2/neu gene amplification in BCA of case #4. The dysplasias adjacent to carcinoma in two cases were classified as not amplified. One dysplasia showed a minor population with Her-2/neu signal cluster. 3.1.5. Evaluation by laser scanning microscopy From the four cases of BCA a total number of 144 283 neoplastic cells were evaluated. In each BCA different fractions of cells with Her-2/neu signal clusters ranging from 7.4 87.0% was present. The remaining cells displayed a varying ratio of Her-2/neu signals/centromere 17 signals reflecting a continuous spectrum of amplification and polysomy, respectively. From the adjacent dyslastic areas of two cases 233 and 264 cell were counted. One of the two dysplastic areas showed a fraction of 12% with Her-2/neu signal cluster. Detailed results are given in Table 1. An example of an sequence of optical sections for signal enumeration is given in Fig. 4. 4. Discussion In this study we used quantitative immunohistochemistry and FISH to determine the extent of intratumoural heterogeneity of c-erbb-2 overexpression and Her-2/neu gene amplification in BCA. Striking intratumoural heterogeneity was observed and quantified at both the phenotypic and genotypic levels in most of the tumours. The heterogeneity that was already evident by visual evaluation of the sections could be confirmed by quantification using digital image analysis and laser scanning microscopy. Four of the six tumours had areas which showed strong overexpression of c-erbb-2,

30 A. Walch et al. / c-erbb-2 overexpression and Her-2/neu gene in BCA Fig. 3. Heterogeneity of Her-2/neu gene amplification in BCA of case #4 shown by dual-colour FISH with Her-2/neu-specific probes (red signals) and chromosome 17 centromeric probes (green signals) counterstained with TO-PRO TM -3 iodide. Note that the tumour cells in the centre of the BCA area show high-level Her-2/neu amplification (clusters), while the remaining tumour cells show no, or only low-level, Her-2/neu amplification. whereas other areas displayed no or only faint cell membrane staining in few tumour cells. Taking the entire tumour area into account, these cases could be still classified as 3+, the highest score according to the most commonly used scoring system (DAKO HercepTest TM ). These results suggest that in small tumour samples of BCA, for example endoscopic biopsies, sampling error could lead to an underestimation of the actual extent of c-erbb-2 expression. Primary BCA and its lymph node metastasis are genetically complex tumours characterized by marked genetic heterogeneity, as we previously demonstrated in a comparative genomic hybridization study [5]. This heterogeneity provides a potential source for the selection of subclones with increased malignant and metastatic potential. Therefore, the intra-tumoural heterogeneity of c-erbb-2 overexpression and Her-2/neu gene amplification described in the present study is not surprising. The impact of this intratumoural heterogeneity on the biological behavior of BCA is not yet clear. However, the treatment of c-erbb-2 overexpressing tumours by c-erbb-2 targeting agents such as Herceptin (Genentech, San Francisco, CA) as already introduced for breast cancer [3] may be less effective in more heterogeneous tumours. In these cases tumour clones without c-erbb-2 overexpression might be unaffected by the specific therapy and could become the dominant clone after treatment. The major advantage of the immunohistochemical and FISH techniques used in our study was that the phenotypic and genotypic analyzes could be performed on a cell-by-cell basis with preservation of morphology. Thus, both methods are especially well suited to study intratumoural heterogeneity. Although heterogeneity of c-erbb-2 overexpression was already evident in our cases by visual evaluation, we used digital imaging analysis to obtain more detailed and objective data. Similarly, FISH signals were evaluated with the

A. Walch et al. / c-erbb-2 overexpression and Her-2/neu gene in BCA 31 Fig. 4. Evaluation of gene copy number changes for Her-2/neu-specific probes (red signals) and chromosome 17 centromeric probes (green signals) counterstained with TO-PRO TM -3 iodide in case #4 using laser scanning microscopy. A sequence of images from an selected areas was scanned in steps of 0.5 µm for signal enummeration. help of laser scanning microscopy. The automated acquisition of images was more accurate than visual evaluation, especially for the evaluation of double color hybridization marking the Her-2/neu locus and the centromeric region of chromosome 17. The use of laser scanning microscopy allowed a more objective determination of the amplification level within subpopulations and the amplification pattern (clusters of amplified genes versus homogenous distribution). In conclusion, we observed marked intratumoural heterogeneity of c-erbb-2 protein over-expression and Her-2/neu gene copy number in the majority of the primary BCA that we analyzed. Digital image analysis and laser scanning microscopy were helpful in quantifying the variations in protein expression and DNA copy number in individual tumour cells. Tumor heterogeneity should be taken into account when the c-erbb- 2 status is determined in small biopsies. Although the biological significance of c-erbb-2 heterogeneity in BCA is not yet clear, it is possible that, in heterogeneous tumours, cells with normal levels of c-erbb-2 protein and Her-2/neu gene copy number could clonally expand during treatment with c-erbb-2 targeting agents. References [1] R.H. Hardwick, N.A. Shepherd, M. Moorghen, P.V. Newcomb and D. Alderson, c-erbb-2 overexpression in the dysplasia/carcinoma sequence of Barrett s oesophagus, J. Clin. Pathol. 48 (1995), 129 132.

32 A. Walch et al. / c-erbb-2 overexpression and Her-2/neu gene in BCA [2] A.H. Hopman, F.C. Ramaekers, A.K. Raap, J.L. Beck, P. Devilee, M. van der Ploeg and G.P. Vooijs, In situ hybridization as a tool to study numerical chromosome aberrations in solid bladder tumours, Histochemistry 89 (1988), 307 316. [3] J.S. Ross and J.A. Fletcher, The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy, Stem Cells 16(6) (1998), 413 428. [4] E. Tzahar and Y. Yarden, The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands, Biochim. Biophys. Acta 1377(1) (1998), M25 37. [5] Walch, H. Zitzelsberger, J. Bruch, G. Keller, D. Angermeier, M. Aubele, J. Mueller, H. Stein, H. Braselmann, J.R. Siewert, H. Höfler and M. Werner, Chromosomal imbalances in Barrett s adenocacrinoma and in the metaplasia-dysplasiacarcinoma-sequence, Am. J. Pathol. (in press). [6] M. Werner, A. Mattis, M. Aubele, M. Cummings, H. Zitzelsberger, P. Hutzler and H. Höfler: 20q13.2 amplification in intraductal hyperplasia adjacent to in situ and invasive ductal carcinoma of the breast, Virchows Arch. (in press). [7] M. Werner, J. Mueller, A. Walch, H. Höfler: The molecular pathology of Barrett s esophagus. Review, Histol. Histopathol. 14(2) (1999), 553 559.